X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-24-2024-1488.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-13-2023-60327.pdf
https://www.fiercepharma.com/pharma/esperion-daiichi-sankyo-milestone-payment-feud-heats-lawsuit
https://www.biopharmadive.com/news/esperion-daiichi-dispute-milestone-heart-drug-results/645204/
https://www.esperion.com/news-releases/news-release-details/esperion-announces-clear-cardiovascular-outcomes-trial-nexletolr
https://www.indiainfoline.com/article/news-top-story/kimia-biosciences-gets-permission-for-bemopedoic-acid-bulk-drug-stock-gains-near--122051800304_1.html
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-lifesciences-launches-drug-for-treating-bad-cholesterol/articleshow/91534465.cms
https://www.esperion.com/news-releases/news-release-details/esperion-supports-collaborative-study-integrated-and-learning
https://www.esperion.com/news-releases/news-release-details/esperion-announces-publication-phase-3-data-bempedoic-acid
https://www.esperion.com/news-releases/news-release-details/esperion-announces-two-nexletolr-bempedoic-acid-data
https://finance.yahoo.com/finance/news/esperion-chops-40-workforce-launch-215424232.html
https://www.biopharmadive.com/news/esperion-layoffs-heart-drug-sales-disappoint/608401/
http://www.pharmatimes.com/news/uk_approval_for_daiichi_sankyos_cholesterol-lowering_treatments_1365458#:~:text=UK%20approval%20for%20Daiichi%20Sankyo's%20cholesterol%2Dlowering%20treatments,-18th%20March%202021&text=Daiichi%20Sankyo's%20cholesterol%2Dlowering%20drugs,for%20use%20on%20the%20NHS.
https://www.globenewswire.com/news-release/2021/03/17/2194920/0/en/NEXLETOL-bempedoic-acid-Tablet-ezetimibe-and-atorvastatin-combination-lowered-bad-cholesterol-by-60-5-vs-placebo-in-Phase-2-study.html
https://www.globenewswire.com/news-release/2020/12/16/2145893/0/en/First-in-class-cholesterol-lowering-treatment-NILEMDO-bempedoic-acid-tablet-and-its-combination-with-ezetimibe-NUSTENDI-bempedoic-acid-and-ezetimibe-tablet-approved-in-Switzerland.html
https://www.fiercepharma.com/pharma/aha-esperion-s-cholesterol-fighter-nexletol-builds-case-doctors-new-data
https://www.globenewswire.com/news-release/2020/11/13/2126564/0/en/NEXLETOL-bempedoic-acid-Tablets-Highlighted-at-AHA-2020-with-Presentations-of-Analyses-Demonstrating-Significant-Low-Density-Lipoprotein-Cholesterol-LDL-C-Lowering-vs-Placebo-in-Ph.html
https://www.fiercepharma.com/marketing/esperion-launches-dtc-campaign-for-nexletol-pandemic-caused-non-traditional-tv-ad-using
http://www.pharmafile.com/news/557748/daiichi-sankyos-nilemdo-significantly-reduces-cholesterol-levels-esc-2020
https://www.globenewswire.com/news-release/2020/08/10/2075927/0/en/Esperion-Reports-Second-Quarter-2020-Financial-Results-and-Provides-Company-Update.html
https://www.ema.europa.eu/en/documents/assessment-report/nilemdo-epar-public-assessment-report_en.pdf
https://www.globenewswire.com/news-release/2020/06/14/2047738/0/en/Esperion-Announces-Pooled-Analysis-from-Phase-3-LDL-C-Lowering-Clinical-Development-Program-of-NEXLETOL-Bempedoic-Acid-Tablets-Presented-at-the-American-Diabetes-Association-80th-S.html
https://www.biospectrumasia.com/news/34/15836/esperion-otsuka-to-develop-treatment-for-hypercholesterolemia.html
https://endpts.com/esperion-strikes-japan-deal-for-goldilocks-cholestrol-drug-bags-60m-cash-as-pandemic-forces-virtual-us-rollout/
https://www.streetinsider.com/Corporate+News/Esperion+Therapeutics+%28ESPR%29+Announces+EC+Approval+of+NUSTENDI+Tablet+for+Treatment+of+Hypercholesterolemia+and+Mixed+Dyslipidemia/16712005.html
https://www.globenewswire.com/news-release/2020/03/23/2004649/0/en/Esperion-Announces-Pooled-Analyses-from-Phase-3-LDL-C-Lowering-Development-Program-of-the-NEXLETOL-bempedoic-acid-Tablet-and-Phase-2-Study-Results-of-the-NEXLIZET-bempedoic-acid-an.html
https://www.fiercepharma.com/marketing/esperion-notches-2nd-fda-approval-cholesterol-lowering-combo-nexlizet
http://www.pmlive.com/pharma_news/esperion_gets_fda_thumbs_up_for_cholesterol_drug_nexletol_1326819
http://www.pharmatimes.com/news/givlaari,_nubeqa_among_jan_chmp_decisions_1323999
https://www.evaluate.com/vantage/articles/events/upcoming-events/go-or-no-go-esperions-double-whammy-and-look-priority
https://www.globenewswire.com/news-release/2020/01/31/1978087/0/en/Esperion-Announces-Positive-CHMP-Opinion-for-the-Marketing-Authorisation-Application-for-Bempedoic-Acid-for-the-Treatment-of-Hypercholesterolemia-and-Mixed-Dyslipidemia.html
https://www.contractpharma.com/contents/view_breaking-news/2019-08-29/esperions-bempedoic-acid-ezetimibe-tablet-achieves-positive-phase-ii-results/
https://www.biospace.com/article/esperion-and-oberland-capital-announce-200-million-funding-agreement/?s=75
https://www.fiercebiotech.com/biotech/esperion-climbs-as-nejm-papers-downplay-cancer-death-data
https://www.prnewswire.com/news-releases/daiichi-sankyo-europe-and-esperion-announce-validation-of-the-marketing-authorisation-application-maa-for-bempedoic-acid-and-the-bempedoic-acid--ezetimibe-fixed-dose-combination-tablet-300804050.html
https://www.fiercebiotech.com/biotech/esperion-s-cholesterol-drug-cuts-ldc-c-phase-3
https://www.fiercepharma.com/marketing/esc-need-to-know-xarelto-flops-pfizer-s-tafamidis-win-entresto-s-early-use-and-more
Market Place
Share 
